This program focuses on the signs and symptoms of multiple sclerosis, its affect on quality of life, and current pharmacologic and rehabilitation treatment options. The program also contains an interesting case study.

Common Misconceptions With Bioequivalence & Interchangeability
Faculty: Andrew J. Pultz, Jr, PharmD, RPh | Joseph F. Dasta, MSc, FCCM, FCCP | Sandra L. Kane-Gill, PharmD, MSc
CE credit hour: 1.0
Bioequivalence is a comparison of two or more products with respect to their bioavailabilities. Bioequivalence of trade and generic products or different dosage forms of the same product needs to be determined before the products can be legally interchanged. Numerous factors can affect bioavailability (and bioequivalence) determinations. Thus, there is a great potential for wide variability among the pharmacokinetic profiles among patient populations and bioequivalence determinations. As pharmacists and Nurses, we are in an optimal position to prevent or intervene when a patient is experiencing drug-drug and drug-food interaction resulting in bioavailability alterations with outcomes including sub-therapeutic responses or adverse events. While product interchange between trade and generic medications or between dosage forms of the same product is typically not a problem this activity is going to highlight some examples of when it is a concern.

All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.